AU2001284321A1 - Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors - Google Patents

Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors

Info

Publication number
AU2001284321A1
AU2001284321A1 AU2001284321A AU8432101A AU2001284321A1 AU 2001284321 A1 AU2001284321 A1 AU 2001284321A1 AU 2001284321 A AU2001284321 A AU 2001284321A AU 8432101 A AU8432101 A AU 8432101A AU 2001284321 A1 AU2001284321 A1 AU 2001284321A1
Authority
AU
Australia
Prior art keywords
composition
mixtures
group
glycol
sorbitan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284321A
Other languages
English (en)
Inventor
Vinod Kumar Arora
Mukesh Kumar
Ajay Kumar Singla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of AU2001284321A1 publication Critical patent/AU2001284321A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001284321A 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors Abandoned AU2001284321A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN779/DEL/2000 2000-08-29
IN779DE2000 IN191090B (cs) 2000-08-29 2000-08-29
PCT/IB2001/001557 WO2002017923A1 (en) 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors

Publications (1)

Publication Number Publication Date
AU2001284321A1 true AU2001284321A1 (en) 2002-03-13

Family

ID=11097085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284321A Abandoned AU2001284321A1 (en) 2000-08-29 2001-08-28 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors

Country Status (13)

Country Link
US (1) US20040029946A1 (cs)
EP (1) EP1315500A4 (cs)
JP (1) JP2004525859A (cs)
CN (1) CN1227012C (cs)
AU (1) AU2001284321A1 (cs)
BR (1) BR0113661A (cs)
CA (1) CA2420804A1 (cs)
CZ (1) CZ2003822A3 (cs)
IN (1) IN191090B (cs)
RU (1) RU2003108335A (cs)
SK (1) SK3622003A3 (cs)
WO (1) WO2002017923A1 (cs)
ZA (1) ZA200301680B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
CA2448627A1 (en) * 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
WO2004000263A1 (en) * 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
AU2003238543B2 (en) * 2002-06-25 2008-02-28 Acrux Dds Pty Ltd Transdermal aerosol compositions
AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
JP4283507B2 (ja) * 2002-08-02 2009-06-24 久光製薬株式会社 経皮投与用貼付剤
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2005027939A1 (en) * 2003-08-21 2005-03-31 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
JP2007510628A (ja) * 2003-10-14 2007-04-26 ダーマトレンズ，インコーポレイティド 親水性薬剤の経皮投与の促進
US20070196301A1 (en) * 2005-12-21 2007-08-23 L'oreal Cosmetic composition with a volumizing effect
FR2894811B1 (fr) † 2005-12-21 2008-02-22 Oreal Composition cosmetique a effet volumateur
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009076302A1 (en) 2007-12-10 2009-06-18 Bayer Healthcare Llc Control markers for auto-detection of control solution and methods of use
EP2658563B1 (en) * 2010-12-28 2017-11-15 Mary Kay, Inc. Sebum control and anti-acne composition
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) * 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
JP6495723B2 (ja) * 2015-04-14 2019-04-03 帝國製薬株式会社 セレコキシブの経皮吸収製剤
CN105663032A (zh) * 2016-02-23 2016-06-15 青岛科技大学 一种维他昔布软膏剂的制备方法
CN107158407A (zh) * 2017-06-17 2017-09-15 安徽仁之堂药业有限公司 一种中药提取所得挥发油的制剂助剂
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2075837B (en) * 1980-05-14 1984-03-14 Hisamitsu Pharmaceutical Co Topical pharmaceutical gel containing anti-inflammatory analgesic agents
US4602040A (en) * 1983-04-18 1986-07-22 Warner-Lambert Company Meclofenamic acid topical pharmaceutical composition
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5807568A (en) * 1994-12-27 1998-09-15 Mcneil-Ppc, Inc. Enhanced delivery of topical compositions containing flurbiprofen
BR9607035A (pt) * 1995-02-13 1997-11-04 Searle & Co Isoxazois substituidos para o tratamento de inflamação
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US5998487A (en) * 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
GB2340751B (en) * 1998-08-12 2003-11-05 Edko Trading Representation Pharmaceutical compositions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
WO2000072883A2 (en) * 1999-06-02 2000-12-07 Aviana Biopharm Pharmaceutical transdermal compositions
IN191512B (cs) * 2000-01-21 2003-12-06 Panacea Biotech

Also Published As

Publication number Publication date
US20040029946A1 (en) 2004-02-12
CA2420804A1 (en) 2002-03-07
EP1315500A1 (en) 2003-06-04
RU2003108335A (ru) 2004-09-10
SK3622003A3 (en) 2003-09-11
WO2002017923A1 (en) 2002-03-07
IN191090B (cs) 2003-09-20
EP1315500A4 (en) 2006-05-31
JP2004525859A (ja) 2004-08-26
BR0113661A (pt) 2004-07-06
ZA200301680B (en) 2004-06-23
CN1469748A (zh) 2004-01-21
CN1227012C (zh) 2005-11-16
CZ2003822A3 (cs) 2003-08-13

Similar Documents

Publication Publication Date Title
US20040029946A1 (en) Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
US5807568A (en) Enhanced delivery of topical compositions containing flurbiprofen
US9675562B2 (en) Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
AU2005221427B2 (en) Novel compositions for topical delivery
US20070280972A1 (en) Adhesive solid gel-forming formulations for dermal drug delivery
US20060211688A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
US20060241175A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
JPH04210914A (ja) 水アルコール性ゲルを用いるイブプロフエンの経皮デリバリー方法
JP2007536312A (ja) 抗コリン作用薬のための透過性増強組成物
US20150297507A1 (en) Diclofenac formulations
US20120157536A1 (en) Composition for transdermal administration of non-steroidal anti-flammatory drug
US20050049291A1 (en) Process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2-enzyme inhibitors
JP4195178B2 (ja) 消炎鎮痛外用剤
WO2006103638A2 (en) Topical pharmaceutical compositions of terbinafine and processes for their preparation
CA2500907A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
US20230226083A1 (en) Compositions and methods for deep dermal drug delivery
JP2001064206A (ja) 経皮吸収促進組成物
KR101894891B1 (ko) 흡수가 증가된 덱시부프로펜 에멀젼 함유 겔 제형
JP2023525160A (ja) 毛包内への生物活性剤の送達のための組成物
TWI308873B (cs)
US11376213B2 (en) Topical pharmaceutical formulation
WO2020086038A2 (en) Topical compositions comprising tolperisone and selective cox-2 inhibitor combination
KR20020061281A (ko) 속효성이고 흡수성이 높은 외용제 조성물

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application